1 day-12.13%
1 week-16.00%
1 month-75.32%
3 months-76.92%
6 months-72.00%
Current year-18.29%
1 week 0.41
Extreme 0.41
0.53
1 month 0.4
Extreme 0.4
1.72
Current year 0.4
Extreme 0.4
3.27
1 year 0.4
Extreme 0.4
3.27
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 2005-12-31
Chief Executive Officer 73 -
Chief Executive Officer 50 2023-12-28
Director TitleAgeSince
Chairman 73 2024-12-15
Director/Board Member 67 2005-12-31
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-12.13%-16.00% - - 1.4M
-0.12%-0.33%+79.39%+288.44% 3.87B
+5.65%-2.16%+255.37%+42.62% 3.69B
-2.76%-3.90%+28.28%+61.61% 3.38B
+0.48%-1.22%+271.47%+503.36% 2.59B
-1.24%-4.30%-29.60%-31.68% 2.08B
-6.10%-9.32%+40.19% - 1.59B
+0.16%0.00%+21.81%+41.80% 1.07B
-2.97%-10.79%+134.05%-37.33% 1B
-1.13%-0.83%+7.74%+53.60% 621M
Average -2.02%-4.69%+89.86%+115.30% 2.21B
Weighted average by Cap. -0.18%-4.29%+111.26%+150.80%
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!